NanoViricides Signs Master Services Agreement with OnlyOrphansCote for Orphan Drug Strategy of NV-387 for MPox, Smallpox, and Measles Treatment

NanoViricides has signed a Master Services Agreement with OnlyOrphansCote to develop an orphan drug strategy for NV-387, a broad-spectrum antiviral drug that could treat Smallpox, MPox, and Measles. The orphan drug designation could qualify the Company for incentives such as tax credits, user fee exemptions, and market exclusivity. NV-387 has demonstrated excellent activity against lethal animal models of orthopoxvirus infections and could be eligible for orphan drug designation for Smallpox, MPox, and Measles treatment.